secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001104659-25-094522
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio appoints Mark Guerin as CFO; base salary $450K plus options for 200K shares
--------------------------------------------------------------------------------

- Mark Guerin appointed CFO effective Sept 25, 2025; previously CFO of Onconova/Traws Pharma (TRAW).
- Compensation: $450K base salary, 40% annual target bonus, options for 200,000 shares, six months severance.
- Guerin holds CPA, CMA, CFM certifications; began career at Coopers & Lybrand.
- No transactions requiring disclosure under Item 404(a) between Guerin and the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925094522/0001104659-25-094522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925094522/tm2527170d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-094522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer